Suppr超能文献

用于测量尿液中人绒毛膜促性腺激素、其β亚基和β核心片段的高灵敏度免疫测定法的开发:在恶性肿瘤中的应用。

Development of highly sensitive immunoassays to measure human chorionic gonadotropin, its beta-subunit, and beta core fragment in the urine: application to malignancies.

作者信息

O'Connor J F, Schlatterer J P, Birken S, Krichevsky A, Armstrong E G, McMahon D, Canfield R E

机构信息

Department of Pathology, College of Physicians and Surgeons, Columbia University, New York, New York 10032.

出版信息

Cancer Res. 1988 Mar 1;48(5):1361-6.

PMID:2449279
Abstract

A variety of malignancies have been associated with the presence of human chorionic gonadotropin, hCG, its subunits, and fragments of its beta-subunit in blood and urine. The usefulness of these hCG-related tumor markers in nontrophoblastic malignancies has been inhibited by inadequate assay techniques. In order to achieve the required sensitivity and specificity, concentration steps and other procedures to remove cross-reacting human luteinizing hormone were necessary. In addition, the coexistence of a fragment of the hCG-beta or beta human luteinizing hormone subunit contributes to significant errors of measurement in urine. The importance of the hCG-beta fragment as a potential tumor marker has been recognized previously but no method was available to measure this antigen readily. We report here the development of a series of radioimmunometric, two-site assays which will accurately measure hCG, hCG-beta subunit, and the beta-subunit fragment directly in small volumes of unprocessed urine. These assays are highly specific, extremely sensitive, and not labor intensive since they employ microtiter plate procedures. Application of these assays to urine samples from patients with gynecological malignancies indicated that over 50% of all patients tested excreted the hCG-beta fragment in their urine. Also, this fragment comprised more than 50% of the moles of hCG immunoreactive components present in the specimens that were positive for hCG. This cancer marker is also demonstrable in trophoblastic malignant states such as choriocarcinoma in which the low molecular weight fragment can also be visualized directly by immunoblotting procedures. We conclude that a search for hCG immunoreactivity in the urine of patients with malignancies will be improved by the inclusion of accurate measurements of the prominent quantities of the beta fragment excreted by these individuals.

摘要

多种恶性肿瘤与血液和尿液中存在人绒毛膜促性腺激素(hCG)、其亚基及其β亚基片段有关。这些与hCG相关的肿瘤标志物在非滋养层恶性肿瘤中的应用因检测技术不足而受到限制。为了达到所需的灵敏度和特异性,浓缩步骤和其他去除交叉反应性人促黄体生成素的程序是必要的。此外,hCG-β或β人促黄体生成素亚基片段的共存会导致尿液测量出现重大误差。hCG-β片段作为一种潜在肿瘤标志物的重要性此前已得到认可,但尚无易于测量该抗原的方法。我们在此报告一系列放射免疫分析双位点分析法的开发,该方法可直接在少量未处理尿液中准确测量hCG、hCG-β亚基和β亚基片段。这些分析具有高度特异性、极高灵敏度,且由于采用微量滴定板程序,无需大量人力。将这些分析应用于妇科恶性肿瘤患者的尿液样本表明,超过50%的受测患者尿液中排出hCG-β片段。此外,在hCG呈阳性的标本中,该片段占hCG免疫反应成分摩尔数的50%以上。这种癌症标志物在滋养层恶性状态如绒毛膜癌中也可检测到,在绒毛膜癌中,低分子量片段也可通过免疫印迹法直接可视化。我们得出结论,通过准确测量这些个体排出的大量β片段,对恶性肿瘤患者尿液中hCG免疫反应性的检测将得到改善。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验